全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Titrimetric and Spectrophotometric Assay of Ganciclovir in Pharmaceuticals Using Cerium(IV) Sulphate as the Oxidimetric Agent

DOI: 10.5402/2012/818405

Full-Text   Cite this paper   Add to My Lib

Abstract:

Titrimetric and spectrophotometric assay of ganciclovir (GNC) is described using cerium(IV) sulphate as the oxidimetric reagent. The methods are based on the oxidation of GNC with a measured excess of cerium(IV) sulphate in acid medium followed by determination of the unreacted oxidant by two different reaction schemes. In titrimetry, the unreacted oxidant was determined by back titration with ferrous ammonium sulphate (FAS) in sulphuric acid medium, and spectrophotometry involves the reaction of residual cerium(IV) with p-DMAB to form brownish-coloured p-dimethylamino quinoneimine whose absorbance was measured at 460?nm. In both methods, the amount of cerium(IV) sulphate reacted corresponds to GNC concentration. Titrimetry is applicable over 3–10?mg range where as, in spcetrophotometry, the calibration graph is linear over the range of 2–10?μg?mL?1 and the calculated molar absorptivity value is 1 . 9 6 0 × 1 0 4 ?L mol?1?cm?1. The validity of the proposed methods was tested by analyzing pure and dosage forms containing GNC. Statistical treatment of the results reflects that the proposed procedures are precise, accurate, and easily applicable for the determination of GNC pure form and in pharmaceutical formulations. 1. Introduction Ganciclovir (GNC) chemically known as 2-amino-9-{[(1,3-dihydroxypropan-2-l)oxy]methyl}-6,9-dihydro-3H-purin-6-one (Figure 1) is a nucleoside analogue widely used in the treatment of cytomegalovirus infections. Figure 1: Structure of Ganciclovir. It has been proved effective against cytomegalovirus in immunocompromised patients, mainly in those with the acquired immunodeficiency syndrome (AIDS), congenital immunodeficiency, or in individuals following organ transplantation [1, 2]. Various techniques have been developed for the determination of GNC in pharmaceuticals. It is official in the United States Pharmacopoeia [3]. The most extensively used technique for the quantitation of ganciclovir is HPLC, but most of the procedures using this technique are devoted to body fluids like plasma [8–18], tissues [19], serum [20], and blood samples [21]. HPLC has also been applied for the determination of GNC in eye drops [22]. GNC in bulk drug and in its formulations has been assayed by UV-spectrometry by measuring the absorbance of drug in 0.1?M HCl and 0.1?M NaOH at 253 and 266?nm, respectively. The methods are reported to be moderately sensitive with molar absorptivity values of ~ 2 . 0 × 1 0 3 . There are only three reports on the use of visible spectrophotometry for the assay of GNC in pharmaceuticals. Schelling et al. [4] have

References

[1]  H. L. Cantrill, K. Henry, N. H. Melroe, W. H. Knobloch, R. C. Ramsay, and H. H. Balfour, “Treatment of cytomegalovirus retinitis with intravitreal ganciclovir. Long-term results,” Ophthalmology, vol. 96, no. 3, pp. 367–374, 1989.
[2]  A. Markham and D. Faulds, “Roxithromycin: an update of its antimicrobial activity, pharmacokinetic properties and therapeutic use,” Drugs, vol. 48, no. 2, pp. 297–326, 1994.
[3]  The United States Pharmacopoeia, XXIV Revision, the National Formulary XIX Rockville, USP Convention, 2000.
[4]  P. Schelling, G. Folkers, and L. Scapozza, “A spectrophotometric assay for quantitative determination of kcat of herpes simplex virus type 1 thymidine kinase substrates,” Analytical Biochemistry, vol. 295, no. 1, pp. 82–87, 2001.
[5]  A. A. Gouda, “Utility of certain σ- and π-acceptors for the spectrophotometric determination of ganciclovir in pharmaceutical formulations,” Talanta, vol. 80, no. 1, pp. 151–157, 2009.
[6]  P. S. Sarsambi, D. Gowrisankar, A. Sonawane, and A. Faheem, “Visible spectrophotometric determination of ganciclovir by condensation and oxidative coupling reactions,” International Journal of ChemTech Research, vol. 2, no. 1, pp. 282–285, 2010.
[7]  N. Wang, Y. Tang, X. Xiong, X. Han, and C. Yu, “A new flow-injection chemiluminescence method for the determination of acyclovir and gancyclovir,” Analytical Letters, vol. 39, no. 5, pp. 973–983, 2006.
[8]  D. R. Weller, H. H. Balfour, and H. E. Vezina, “Simultaneous determination of acyclovir, ganciclovir, and (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in human plasma using high-performance liquid chromatography,” Biomedical Chromatography, vol. 23, no. 8, pp. 822–827, 2009.
[9]  A. Maes, B. Garré, N. Desmet et al., “Determination of acyclovir in horse plasma and body fluids by high-performance liquid chromatography combined with fluorescence detection and heated electrospray ionization tandem mass spectrometry,” Biomedical Chromatography, vol. 23, no. 2, pp. 132–140, 2009.
[10]  Y. J. Dao, Z. Jiao, and M. K. Zhong, “Simultaneous determination of aciclovir, ganciclovir, and penciclovir in human plasma by high-performance liquid chromatography with fluorescence detection,” Journal of Chromatography B, vol. 867, no. 2, pp. 270–276, 2008.
[11]  M. Kasiari, E. Gikas, S. Georgakakou, M. Kazanis, and I. Panderi, “Selective and rapid liquid chromatography/negative-ion electrospray ionization mass spectrometry method for the quantification of valacyclovir and its metabolite in human plasma,” Journal of Chromatography B, vol. 864, no. 1-2, pp. 78–86, 2008.
[12]  N. Perrottet, A. Beguin, P. Meylan et al., “Determination of aciclovir and ganciclovir in human plasma by liquid chromatography-spectrofluorimetric detection and stability studies in blood samples,” Journal of Chromatography B, vol. 852, no. 1-2, pp. 420–429, 2007.
[13]  F. Schenkel, S. Rudaz, Y. Daali, M. K. Oestreicher, J. L. Veuthey, and P. Dayer, “Development and validation of a new reversed-phase ion pairing liquid chromatographic method with fluorescence detection for penciclovir analysis in plasma and aqueous humor,” Journal of Chromatography B, vol. 826, no. 1-2, pp. 1–7, 2005.
[14]  D. Teshima, K. Otsubo, T. Yoshida, Y. Itoh, and R. Oishi, “A simple and simultaneous determination of acyclovir and ganciclovir in human plasma by high-performance liquid chromatography,” Biomedical Chromatography, vol. 17, no. 8, pp. 500–503, 2003.
[15]  S. Kishino, Y. Takekuma, M. Sugawara et al., “Liquid chromatographic method for the determination of ganciclovir and/or acyclovir in human plasma using pulsed amperometric detection,” Journal of Chromatography B, vol. 780, no. 2, pp. 289–294, 2002.
[16]  N. Shibata, A. Kitamura, Y. Yoshikawa, T. Inoue, T. Bamba, and K. Takada, “Simultaneous determination of aciclovir and ganciclovir in plasma by HPLC and pharmacokinetic interactions,” Pharmacy and Pharmacology Communications, vol. 6, no. 11, pp. 501–506, 2000.
[17]  R. Boulieu, N. Bleyzac, and S. Ferry, “High-performance liquid chromatographic determination of ganciclovir in plasma,” Journal of Chromatography, vol. 567, no. 2, pp. 480–484, 1991.
[18]  T. Yoshida, R. Takahashi, K. Imai, H. Uchida, Y. Arai, and T. Oh-Ishi, “A simple, sensitive determination of ganciclovir in infant plasma by high-performance liquid chromatography with fluorescence detection,” Journal of Chromatographic Science, vol. 48, no. 3, pp. 208–211, 2010.
[19]  S. D. Brown, C. A. White, and M. G. Bartlett, “Hydrophilic interaction liquid chromatography/electrospray mass spectrometry determination of acyclovir in pregnant rat plasma and tissues,” Rapid Communications in Mass Spectrometry, vol. 16, no. 19, pp. 1871–1876, 2002.
[20]  M. Koel and P. Nebinger, “HPLC determination of serum ganciclovir using ultrafiltration, ultraviolet and fluorescence detection,” Journal of Pharmaceutical and Biomedical Analysis, vol. 12, no. 3, pp. 429–432, 1994.
[21]  R. Boulieu and N. Bleyzac, “Stability of ganciclovir in blood samples,” Journal of Pharmaceutical and Biomedical Analysis, vol. 12, no. 9, pp. 1205–1207, 1994.
[22]  G. L. Liang and Henan, “HPLC determination of ganciclovir and ribavirin in eye drops,” Yaowu Fenxi Zazhi, vol. 26, no. 9, pp. 1308–1310, 2006.
[23]  International Conference On Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R1), Complementary Guideline on Methodology, London, UK, November 1996, incorporated in November 2005.
[24]  J. Basset, R. C. Denney, G. H. Jeffery, and J. Mendham, Vogel's Quantitative Inorganic Analysis, English Language Book Society and Longman, Essex, UK, 4th edition, 1978.
[25]  A. I. Vogel, A Text-Book of Quantitative Inorganic Analysis Including Elementary Instrumental Analysis, 1961.
[26]  I. A. Darwish, S. A. Hussein, A. M. Mahmoud, and A. I. Hassan, “Spectrophotometric determination of H2-receptor antagonists via their oxidation with cerium(IV),” Spectrochimica Acta—Part A, vol. 69, no. 1, pp. 33–40, 2008.
[27]  N. Rajendraprasad, K. Basavaiah, and K. B. Vinay, “Volumetric and spectrophotometric determination of oxcarbazepine in tablets,” Acta Chimica Slovenica, vol. 58, no. 3, pp. 621–628, 2011.
[28]  K. Basavaiah, V. Ramakrishna, and U. R. A. Kumar, “Use of ceric ammonium sulphate and two dyes, methyl orange and indigo carmine, in the determination of lansoprazole in pharmaceuticals,” Acta Pharmaceutica, vol. 57, no. 2, pp. 211–220, 2007.
[29]  R. A. Kaselis, W. Leibmann, W. Seaman, J. P. Sickels, E. I. Stearns, and J. T. Woods, “Modified colorimetric assay of pteroylglutamic acid,” Analytical Chemistry, vol. 23, no. 5, pp. 746–751, 1951.
[30]  G. D. Christian, Text Book of “Analytical Chemistry”, John Wiley & Sons, Singapore, 2007.
[31]  G. H. Jeffery, J. Bassett, J. Mendham, and R. C. Dennery, Vogel’s Textbook of Quantitative Chemical Analysis, The Bath Press, Great Britain, UK, 5th edition, 1989.
[32]  B. R. DasGupta and D. A. Boroff, “Quantitative spectrophotometric determination of hydrogen peroxide with para-dimethylaminobenzaldehyde,” Analytical Chemistry, vol. 40, no. 13, pp. 2060–2062, 1968.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133